IN SILICO INVESTIGATION OF SMALLANTHUS SONCHIFOLIUS COMPOUNDS AS DPP-4 INHIBITORS FOR ANTIDIABETIC MECHANISMS
DOI:
https://doi.org/10.22159/ijap.2025v17i2.52741Keywords:
Smallanthus sonchifolius, In-silico, DPP-4 inhibitorAbstract
Objective: Smallanthus sonchifolius has been scientifically demonstrated to possess antidiabetic activity through the inhibition of DPP-4 in in-vitro studies. However, there is still a lack of comprehensive research identifying the specific bioactive compounds responsible for this effect. This research specifically aims to explore the potential of bioactive compounds from Smallanthussonchifoliusas DPP-4 inhibitors, a known target for antidiabetic treatment, using in silico techniques.
Methods: The methodologies employed in this study includedmolecular docking, ADMET prediction, and molecular dynamics simulation. The docking process was conducted on 20 test compounds against native ligands within the receptor designated by code 3G0B, as well as against comparative compounds.
Results: Molecular docking analysis revealed four compounds—3,4-dicaffeoylquinic acid, Nystose, 1,3-O-dicaffeoylquinic acid, and 3,5-dicaffeoylquinic acid—that exhibited lower rerank scores than the positive control, alogliptin. Further investigation through molecular dynamics simulations demonstrated that the Nystose-ligand complex displayed stable binding dynamics similar to alogliptin, maintaining consistent interactions throughout the simulation. Key amino acid residues, including Glu205, Glu206, Ser209, Tyr547, Tyr662, and Ser630, were involved in critical hydrogen bonding, contributing to the stability of the Nystose complex. However, despite its promising binding profile, Nystose is predicted to have limited intestinal absorption due to the high number of polar substituents, which may impact its bioavailability.
Conclusion: Nystose is predicted to act as a DPP-4 inhibitor for diabetes treatment, based on findings from molecular docking and molecular dynamics simulations.
Downloads
References
International Diabetes Federation. International Diabetes Federation. 10TH ed. Boyko EJ, Magliano DJ, Karuranga S, Piemonte L, Riley P, Saeedi P, et al., editors. IDF Diabetes Atlas, 10th edition. 2021.
Salvo F, Moore N, Arnaudl M, Robinson P, Raschi E, De Ponti F, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycemia: Systematic review and meta-analysis. BMJ. 2016;353:1–9.
D’Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients with Type 2 Diabetes and Varying Baseline HbA1cLevels. JAMA Intern Med. 2023;183(3):242–54.
Natale P, Palmer SC, Tunnicliffe DJ, Toyama T, Strippoli GFM. Thiazolidinediones for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2023;2023(9).
Chandra V, Yadav P, Raghuvanshi V, Pandey P. Diabetes and Ethnomedicine a Comprehensive Review of Scientific Literature on Traditional Medical Practices. J Pharm Res. 2023;8(2).
Riyanti S, Suganda AG, Sukandar EY. Dipeptidyl peptidase-IV inhibitory activity of some Indonesian medicinal plants. Asian J Pharm Clin Res. 2016;9(2):375–7.
Baroni S, Suzuki-Kemmelmeier F, Caparroz-Assef SM, Cuman RKN, Bersani-Amado CA. Effect of crude extracts of leaves of Smallanthus sonchifolius (yacon) on glycemia in diabetic rats. Rev Bras Ciencias Farm J Pharm Sci. 2008;44(3):521–30.
Hachkova H, Nagalievska M, Soliljak Z, Kanyuka O, Kucharska AZ, Sokół-łętowska A, et al. Medicinal plants galega officinalis l. And Yacon leaves as potential sources of antidiabetic drugs. Antioxidants. 2021;10(9).
Brogi S, Ramalho TC, Kuca K, Medina-Franco JL, Valko M. Editorial: In silico Methods for Drug Design and Discovery. Front Chem. 2020;8(August):1–5.
Prasetiyo A, Mumpuni E, Luthfiana D, Herowati R, Putra GS. In silico discovery of potential sodium-glucose cotransporter-2 ( SGLT-2 ) inhibitors from Smallanthus sonchifolius ( Poepp .) H . Rob . via molecular docking and molecular dynamics simulation approach. 2025;13(3):716–28.
Komura H, Watanabe R, Mizuguchi K. The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery. Pharmaceutics. 2023;15(11):1–30.
Bitencourt-Ferreira G, de Azevedo WFJ. Molegro Virtual Docker for Docking. Methods Mol Biol. 2019;2053:149–67.
Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key topics in molecular docking for drug design. Int J Mol Sci. 2019;20(18):1–29.
Prasetiyo A, Kumala S, Mumpuni E, Tjandrawinata RR. Validation of structural-based virtual screening protocols with the PDB Code 3G0B and prediction of the activity of Tinospora crispa compounds as inhibitors of dipeptidyl-peptidase-IV. Res Results Pharmacol. 2022;8(1):95–102.
Edache EI, Uzairu A, Shallangwa GA, Mamza PA. Virtual screening, pharmacokinetics, and molecular dynamics simulations studies to identify potent approved drugs for Chlamydia trachomatis treatment. Futur J Pharm Sci. 2021;7(1).
Farkhani A, Sauriasari R, Yanuar A. In Silico approach for screening of the Indonesian medicinal plant's database to discover potential dipeptidyl peptidase-4 inhibitors. Int J Appl Pharm. 2020;12(Special Issue 1):60–8.
Bitew M, Desalegn T, Demissie TB, Belayneh A, Endale M, Eswaramoorthy R. Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study. PLoS One. 2021;16(12 December).
Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8(1).
Yogini CSAIK, Kumar CS, Anuradha CM, Chitturi CHMK. Computational assessment of Undaria pinnatifida and Moringa oleifera compounds as anti-obesity agents. 2024;16(5).
Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. Curr Top Med Chem. 2019;19(18):1621–49.
Prasetiyo A, Mumpuni E, Luthfiana D, Herowati R, Putra GS. In silico discovery of
potential sodium-glucose cotransporter-2 ( SGLT-2 ) inhibitors from Smallanthus
sonchifolius ( Poepp .) H . Rob . via molecular docking and molecular dynamics
simulation approach. 2025;13(3):716–28. [22] Imai M, Yamane T, Kozuka M, Takenaka S, Sakamoto T, Ishida T, et al. Caffeoylquinic acids from aronia juice inhibit both dipeptidyl peptidase IV and α-glucosidase activities. Lwt. 2020;129(February):109544.
Alam S, Sarker MMR, Sultana TN, Chowdhury MNR, Rashid MA, Chaity NI, et al. Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front Endocrinol (Lausanne). 2022;13(February).
Batool M, Ahmad B, Choi S. A structure-based drug discovery paradigm. Int J Mol Sci. 2019;20(11).
Du X, Li Y, Xia YL, Ai SM, Liang J, Sang P, et al. Insights into protein–ligand interactions: Mechanisms, models, and methods. Int J Mol Sci. 2016;17(2):1–34.
C ZF, James JP, Srinivasa MG, Sindhu TJ, Jouhara BM, Revanasiddappa BC, et al. Invetigating multi-target potential of Mucuna pruriens against Parkinson’s disease : Insight from molecular docking, MMGBSA, pharmacophore modeling, MD simulation, and ADMET analysis. 2024;16(5).
Odhar HA. Molecular docking and dynamics simulation analysis of the human FXIIa with compounds from the Mcule database. Bioinformation. 2023;19(2):160–6.
Istyastono EP, Riswanto FDO. Molecular Dynamics Simulations of the Caffeic Acid Interactions To Dipeptidyl Peptidase Iv. Int J Appl Pharm. 2022;14(4):274–8.
Published
How to Cite
Issue
Section
Copyright (c) 2024 NOVI YANTIH, ZUHELMI AZIZ, ESTI MUMPUNI, NURUL WIDAYANTI, ANDRI PRASETIYO
This work is licensed under a Creative Commons Attribution 4.0 International License.
